Grandfield & Dodd LLC Acquires 611 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Grandfield & Dodd LLC lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,207 shares of the biopharmaceutical company's stock after buying an additional 611 shares during the period. Regeneron Pharmaceuticals makes up 1.3% of Grandfield & Dodd LLC's portfolio, making the stock its 27th biggest position. Grandfield & Dodd LLC's holdings in Regeneron Pharmaceuticals were worth $21,061,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Capital International Investors lifted its holdings in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after buying an additional 1,390,534 shares during the period. Geode Capital Management LLC increased its position in Regeneron Pharmaceuticals by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after acquiring an additional 155,369 shares during the last quarter. Dodge & Cox lifted its holdings in Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock valued at $1,653,543,000 after acquiring an additional 9,381 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after acquiring an additional 810,144 shares during the period. Finally, Franklin Resources Inc. boosted its position in Regeneron Pharmaceuticals by 7.9% in the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock worth $1,456,864,000 after purchasing an additional 149,124 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

REGN has been the topic of several recent research reports. UBS Group increased their price objective on shares of Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the stock a "neutral" rating in a research note on Friday, July 11th. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target on the stock. BMO Capital Markets dropped their price target on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research note on Monday, June 2nd. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and reduced their price objective for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Finally, JPMorgan Chase & Co. decreased their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $823.54.

Regeneron Pharmaceuticals Price Performance

REGN traded down $0.03 during trading on Wednesday, hitting $547.93. 1,089,394 shares of the company traded hands, compared to its average volume of 922,147. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The company has a market cap of $59.15 billion, a PE ratio of 13.95, a P/E/G ratio of 2.03 and a beta of 0.33. The stock's 50-day simple moving average is $544.35 and its two-hundred day simple moving average is $617.69. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period last year, the company earned $9.55 EPS. The firm's revenue for the quarter was down 3.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.64%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.